MedPath

To Compare and Evaluate the Effect of Duchenne Muscular Dystrophy affected Patients Undergoing Current TreatmentAlong with Food Supplements

Not Applicable
Completed
Conditions
Health Condition 1: M638- Disorders of muscle in diseases classified elsewhere
Registration Number
CTRI/2021/05/033346
Lead Sponsor
ichiIn Biosciences Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
28
Inclusion Criteria

1. Subject who diagnosed with DMD

2. Aged from 6-18

3. Patients who are to participate in the study with a written inform consent form.

Exclusion Criteria

Subjects who are not a part of any clinical studies prior to 30 days.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Observation of changes in the levels of IL-6 and Myoglobin urea from the baseline.Timepoint: Day 45±1
Secondary Outcome Measures
NameTimeMethod
1. Measurement of the levels of CK, Titin, TNF, Haptoglobin, Dystrophin level, LFT,CBC,Cystatin C <br/ ><br>2. Immunological Parameters: IL-13,CD-40,ESR <br/ ><br>Timepoint: Day 1, Day21 ± 1, Day 45±1 and Monitoring Adverse events each visits <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath